STOCK TITAN

Aurora Cannabis Inc - ACB STOCK NEWS

Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.

Aurora Cannabis Inc. (ACB) is a globally recognized leader in medical and recreational cannabis production, operating advanced facilities that meet stringent international standards. This page serves as the definitive source for verified news and official announcements impacting ACB's market position and strategic initiatives.

Access real-time updates including quarterly earnings, regulatory compliance milestones, product launches, and partnership agreements. Investors will find essential details on operational expansions, while analysts gain insights into ACB's research-driven approach to cannabis cultivation and global distribution strategies.

Key coverage areas span clinical trial developments, international market entries, sustainability initiatives, and innovations in cannabis-derived health products. All content is curated to meet investor-grade reliability standards, sourced directly from company filings and accredited industry publications.

Bookmark this page for streamlined access to ACB's evolving narrative in the global cannabis sector. Combine our updates with Stock Titan's financial tools to monitor market reactions and long-term trends.

Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company, has announced its upcoming third quarter 2025 financial results conference call. The event is scheduled for Wednesday, February 5, 2025, at 8:00 a.m. Eastern Time (6:00 a.m. Mountain Time). The company will release its financial results before markets open on the same day.

The conference call will be hosted by Miguel Martin, Executive Chairman and CEO, and Simona King, CFO, and will include a question and answer session. Investors can access the webcast through the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
conferences earnings
-
Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) has launched an internship program at its EU-GMP facility in Leuna, Germany, partnering with Erfurt University of Applied Sciences. The six-month program targets students from the Horticultural Crop Production course, offering hands-on experience in medical cannabis cultivation.

The program will cover all aspects of medical cannabis production, including cloning, care, harvesting, packaging, and cleaning, along with participation in research and development projects. The Leuna facility is among the few sites in Germany authorized to grow medical cannabis, featuring state-of-the-art indoor cultivation methods and sustainable practices.

According to Michael Simon, President of Aurora Europe (Interim), this initiative aims to provide students with unparalleled industry insights while collaborating with leading experts in the global medical cannabis sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
none
-
Rhea-AI Summary

Aurora Cannabis Inc. (NASDAQ: ACB) has announced a distribution partnership between MedReleaf Australia and The Entourage Effect to expand access to premium medical cannabis products in Australia. The Entourage Effect will serve as a wholesaler for MedReleaf Australia's portfolio, including CraftPlant, Aurora, and IndiMed brands.

The partnership aims to strengthen Aurora's distribution network in Australia through MedReleaf Australia, its wholly-owned subsidiary that meets TGA-GMP standards. This collaboration represents Aurora's commitment to expanding its presence in the growing Australian medical cannabis market while ensuring broader access to their medical cannabis portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
partnership
Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) has announced new medical cannabis product developments from its research facility, Aurora Coast. The company introduced several innovations including: Aurora CBD Varius (1g, 510 Cartridge), MedReleaf Esprit De Corps (5g and 15g) with 20-29% THC, MedReleaf Sedamen (1g, 510 Cartridge), MedReleaf Noculus (5g and 15g) with 25-31% THC, and WMMC Seasonal Stash - Frosted Alpine (10g) with 24-30% THC. These products are available through AuroraMedical.com, demonstrating Aurora's commitment to providing patients with premium cannabis products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
none
-
Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) announces expansion of its recreational product portfolio with new offerings across Greybeard, San Rafael '71, and Tasty's brands. The new lineup includes Greybeard's Banana Gas Pure Live Resin Vape, Country Lemon Terp Slush, and Critical Diesel Pre-Rolls; San Rafael '71's 20 Pack Pre-Rolls; and Tasty's Diamond Infused Pre-Rolls in Mango, Honeydew, and Melon varieties, plus a Grape 510 Vape. These products focus on delivering premium, science-driven offerings with emphasis on flavor and intensity for Canadian cannabis consumers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
Rhea-AI Summary

Aurora Cannabis reported strong fiscal Q2 2025 results with record adjusted EBITDA of $10.1 million, up 210% year-over-year. Total net revenue reached $81.1 million, a 29% increase driven by 41% growth in global medical cannabis and 21% growth in plant propagation. International revenue grew 93% to $35 million, exceeding Canadian Medical revenue for the first time. The company maintains a strong balance sheet with $152 million in cash and a debt-free cannabis business. Medical cannabis contributed 76% of consolidated net revenue with a 68% adjusted gross margin. The company reaffirms its target of positive free cash flow by December 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.2%
Tags
Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company, has announced its upcoming second quarter 2025 earnings conference call scheduled for Wednesday, November 6, 2024, at 8:00 a.m. Eastern Time. The financial results will be released before market opening on the same day. Chairman and CEO Miguel Martin and CFO Simona King will host the conference call and Q&A session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
conferences earnings
-
Rhea-AI Summary

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), in partnership with MedReleaf Australia, has launched an enhanced range of premium medical cannabis oils in Australia. The new products include various cannabinoid ratios to meet diverse patient needs, such as Aurora THC 25 (Sativa and Indica), Aurora 12.5:12.5, Aurora 50:50, and Aurora 10:100 oils, all in 30mL bottles.

These oils are developed and manufactured at Aurora's Canadian TGA and EU GMP certified facility, offering healthcare providers and patients a broader selection of treatment options. The expanded product portfolio demonstrates Aurora's commitment to advancing patient care through high-quality, science-driven cannabis solutions.

Key features of the new cannabis oil products include comprehensive cannabinoid profiles, high standards of quality and safety, and a broad selection for customized patient care. Healthcare professionals can contact MedReleaf Australia's clinical support team for additional information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
none
-
Rhea-AI Summary

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has announced a research collaboration with the University of British Columbia (UBC), funded by Genome British Columbia. The project, titled 'Genomics-enabled Aroma Breeding in Cannabis,' aims to validate genetic and chemical markers for fruity aroma in cannabis, a key consumer preference trait.

Led by Dr. Jose Celedon from Aurora and Professor Joerg Bohlmann from UBC, this research aligns with Aurora's breeding goals and will enhance its breeding program's accuracy and efficiency. The project will utilize Aurora's advanced cannabis genetic library and recent patents on fruity aroma markers. Aurora will contribute through sensory analysis and bioinformatic analyses, while UBC will focus on sequencing transcriptomes, analyzing volatile chemistry, and characterizing genes responsible for fruity aromas.

This collaboration demonstrates Aurora's commitment to innovation and scientific advancement in the cannabis sector, potentially impacting future product development and consumer satisfaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
Rhea-AI Summary

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has announced significant changes to its Board leadership. CEO Miguel Martin has been appointed as Executive Chairman, while outgoing Chairman Ron Funk has been named Lead Independent Director. These appointments, effective immediately, were unanimously approved by Aurora's Board.

Martin, who has served as CEO since September 2020, will continue in this role while taking on additional responsibilities as Executive Chairman. The Board believes this combination of roles will promote strong leadership and efficient decision-making as Aurora aims for global growth.

In other Board changes, Michael Singer has been appointed to the Audit Committee and the Human Resource and Compensation Committee, while Rajesh Uttamchandani joins the HRCC and the Nominating & Corporate Governance Committee. These appointments are expected to bring valuable expertise to their respective committees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
management

FAQ

What is the current stock price of Aurora Cannabis (ACB)?

The current stock price of Aurora Cannabis (ACB) is $4.64 as of April 30, 2025.

What is the market cap of Aurora Cannabis (ACB)?

The market cap of Aurora Cannabis (ACB) is approximately 241.5M.
Aurora Cannabis Inc

Nasdaq:ACB

ACB Rankings

ACB Stock Data

241.49M
54.76M
13.95%
7.88%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Edmonton